Trademark: VERISTRAT 1464428
Word
VERISTRAT
ID
1464428
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
08 December 2011
Registration Date
08 December 2011
Renewal Date
08 December 2031
Service
Spruson & Ferguson
Goods and Services:
Class 35:
Providing marketing information to provide information regarding tests prognostic or predictive of patient benefit from treatment with therapies or a combination of therapies, including anti-cancer drugs for cancer
Providing marketing information to provide information regarding tests prognostic or predictive of patient benefit from treatment with therapies or a combination of therapies, including anti-cancer drugs for cancer
Class 42:
Scientific research services; medical research services; scientific testing services; research and discovery services related to developing prognostic and predictive tests to determine whether patients or a subgroup of patients are likely to benefit from treatment with therapies or combination of therapies intended to treat a disease or disorder, including anti-cancer drugs for cancer; laboratory testing services, including providing prognostic and predictive tests to determine whether patients or a subgroup of patients are likely to benefit from treatment with therapies or combination of therapies intended to treat a disease or disorder, including anti-cancer drugs for cancer, based on mass spectral analysis of clinical specimens; providing an interactive website to provide information regarding tests prognostic or predictive of patient benefit from treatment with therapies or combination of therapies, including anti-cancer drugs for cancer; test results reports providing results of test services, namely reports indicating whether a patient is likely to benefit from treatment with therapies or combination of therapies intended to treat a disease or disorder, including anticancer drugs for cancer
Scientific research services; medical research services; scientific testing services; research and discovery services related to developing prognostic and predictive tests to determine whether patients or a subgroup of patients are likely to benefit from treatment with therapies or combination of therapies intended to treat a disease or disorder, including anti-cancer drugs for cancer; laboratory testing services, including providing prognostic and predictive tests to determine whether patients or a subgroup of patients are likely to benefit from treatment with therapies or combination of therapies intended to treat a disease or disorder, including anti-cancer drugs for cancer, based on mass spectral analysis of clinical specimens; providing an interactive website to provide information regarding tests prognostic or predictive of patient benefit from treatment with therapies or combination of therapies, including anti-cancer drugs for cancer; test results reports providing results of test services, namely reports indicating whether a patient is likely to benefit from treatment with therapies or combination of therapies intended to treat a disease or disorder, including anticancer drugs for cancer